Acorn Capital Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Acorn Capital Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,418,995	Closed	-$15.4M	–	22
2025 Q2	$15.4M	Buy	3,418,995 +183,608	+6%	+$825K	10.09%	3
2025 Q1	$14.3M	Buy	3,235,387 +373,562	+13%	+$2.17M	9.56%	3
2024 Q4	$22.4M	Buy	+2,861,825	New	+$34.9M	12.06%	2

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Acorn Capital Advisors's YMAB Position: Q3 2025 in Review

Acorn Capital Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 3,418,995 shares — an estimated $15.4M sold.

Acorn Capital Advisors first reported a position in YMAB in Q4 2024 and held it in 3 quarters. The position peaked at $22.4M in Q4 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Acorn Capital Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Acorn Capital Advisors sold 3,418,995 Y-mAbs Therapeutics shares in Q3 2025, an estimated $15.4M.
Acorn Capital Advisors first reported a position in Y-mAbs Therapeutics in Q4 2024 and held it in 3 quarters.
Acorn Capital Advisors's Y-mAbs Therapeutics position peaked at $22.4M in Q4 2024.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Acorn Capital Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.